(Q38053442)

27 August 2017

title

Primary CNS lymphoma: a clinician's guide (English)

1 reference

27 August 2017

Niklas Schäfer

1

1 reference

27 August 2017

Martin Glas

series ordinal

2

1 reference

27 August 2017

Ulrich Herrlinger

series ordinal

3

1 reference

27 August 2017

publication date

1 October 2012

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

27 August 2017

published in

1 reference

27 August 2017

volume

12

1 reference

27 August 2017

issue

10

1 reference

27 August 2017

page(s)

1197-1206

1 reference

Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Prolonged corticosteroid-induced remission in primary central nervous system lymphoma: report of a case and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Primary central nervous system lymphoma can be histologically diagnosed after previous corticosteroid use: a pilot study to determine whether corticosteroids prevent the diagnosis of primary central nervous system lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Primary central nervous system lymphomas (PCNSL): MRI response criteria revised.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

International study on low-grade primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Gene expression and angiotropism in primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Primary CNS lymphoma: a whole-brain disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

High-dose methotrexate for elderly patients with primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Monotherapy with methotrexate for primary central nervous lymphoma has single agent activity in the absence of radiotherapy: a single institution cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

High-dose methotrexate based chemotherapy with deferred radiation for treatment of newly diagnosed primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Cognitive functions in survivors of primary central nervous system lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Cognitive status and quality of life after treatment for primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Cognitive functions in primary CNS lymphoma after single or combined modality regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Primary central nervous system lymphoma: a role for adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Primary intracerebral malignant lymphoma: report of 248 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Primary central nervous system lymphoma 1991-1997: outcome and late adverse effects after combined modality treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Ifosfamide or trofosfamide in patients with intraocular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Relevance of intraocular involvement in the management of primary central nervous system lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Central nervous system metastases from non-Hodgkin's lymphoma: treatment and prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

High-dose methotrexate for isolated central nervous system relapse in patients with testicular non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Long survival in patients with acquired immune deficiency syndrome-related primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Prospective trial on topotecan salvage therapy in primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

Second-line treatment for primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.120

21 January 2018

Identifiers

DOI

10.1586/ERN.12.120

1 reference

release_o6sk6abzmzez3k2tq3r3gn76vq

27 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/o6sk6abzmzez3k2tq3r3gn76vq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference